Mature B Cells (CD20+)

If you are starting or already taking a medication like rituximab or ocrelizumab, this single number tells you whether the drug is doing what it is supposed to do inside your body. These therapies work by wiping out your CD20-positive (CD20+) B cells, the cells that drive certain autoimmune diseases and B-cell cancers. Without checking this count, you cannot tell whether your treatment is fully active, wearing off, or showing early signs of B-cell return.

Beyond drug monitoring, this test offers a rare look at one specific arm of your immune system: the cells responsible for producing antibodies and remembering past infections. A standard complete blood count tells you total white cells and total lymphocytes, but it cannot separate B cells from T cells, let alone tell you which B cells are mature and ready to act.

What CD20+ Mature B Cells Actually Are

CD20 (full name: cluster of differentiation 20) is a protein that sits on the surface of B cells starting from a late developmental stage and disappearing once those cells become antibody-secreting plasma cells. So when a lab measures CD20+ mature B cells in your blood, it is counting B cells caught in the active middle of their lifecycle: ready to recognize foreign material, multiply, and either pump out antibodies or hold the memory of an infection for years.

These cells start in your bone marrow and finish maturing in your lymph nodes, spleen, and gut tissue. CD20 itself is involved in how B cells move calcium across their membrane, which controls when they activate and divide. People born without working CD20 have normal numbers of B cells but cannot mount strong antibody responses to certain types of bacterial sugars, which has been documented in human case studies.

Why It Matters for Autoimmune Disease

In several autoimmune conditions, B cells stop tolerating your own tissues and start producing antibodies against them. Targeting and removing CD20+ B cells has become a standard approach across multiple sclerosis, rheumatoid arthritis, ANCA-associated vasculitis, lupus nephritis, primary Sjögren's syndrome, and some forms of nephrotic syndrome. Tracking CD20+ B cells in your blood is the cleanest way to confirm that the depletion is working and to time future doses.

Research in primary Sjögren's syndrome shows the naive subset of CD20+ B cells expands while protective regulatory and switched memory B cells shrink, and these shifts track with disease activity. In thymoma-associated myasthenia gravis, the ratio of CD19 to CD20 cells and the balance of memory versus naive cells correlates with how severe the disease is.

Why It Matters for B-Cell Cancers

Most non-Hodgkin lymphomas, chronic lymphocytic leukemia (CLL), and related B-cell cancers grow from CD20+ cells. That is why CD20 has become one of the most successful targets in cancer therapy: drugs like rituximab, obinutuzumab, and newer bispecific antibodies (epcoritamab, odronextamab, glofitamab) all rely on the malignant cells displaying CD20. Loss of CD20 expression is one of the main ways these cancers become resistant to treatment, which has been documented in pediatric patients with relapsed B-cell lymphomas and leukemias.

Outside of treatment monitoring, abnormal CD20+ B-cell populations have been detected in the blood of people living with HIV before they develop non-Hodgkin lymphoma, suggesting that careful immune profiling can sometimes catch warning signs early.

Why It Matters for Antibody Production and Infection Risk

When CD20+ B cells are depleted by therapy, antibody production downstream can drop. Studies of patients on long-term anti-CD20 treatment have shown that some develop low immunoglobulin levels, a condition called secondary hypogammaglobulinemia, which can raise the risk of serious infections. Knowing your CD20+ B-cell count, especially together with antibody (immunoglobulin) levels, helps you and your physician decide whether to continue, pause, or modify treatment.

During the COVID-19 pandemic, people on B-cell-depleting therapy had longer infections and weaker antibody responses to both the virus and vaccines, evidence that CD20+ B cells are the workforce behind durable vaccine protection.

Reference Ranges

There is no universal, guideline-endorsed reference range for CD20+ mature B cells in healthy adults. The most rigorous published reference data come from a study of 483 bone marrow biopsies (ages 1 month to 90 years) that established age-specific ranges, but those values are for marrow tissue, not peripheral blood. For peripheral blood, labs typically report what their own equipment and reference population produce, and ranges can differ noticeably between flow cytometry platforms.

This is why your absolute number matters less than your trend. A CD20+ B-cell count near zero is the expected result on active anti-CD20 therapy. A reappearing count weeks or months after the last infusion signals that the drug effect is fading. Compare your results within the same lab over time for the most meaningful trend.

Tracking Your Trend

A single CD20+ B-cell measurement is rarely enough to act on. Counts shift with recent infections, the timing of your last dose of B-cell-modifying therapy, and even the specific flow cytometry method used. What matters is the trajectory.

If you are starting anti-CD20 therapy, get a baseline before your first dose, then a follow-up several weeks later to confirm depletion. From there, retest every 3 to 6 months to watch for reconstitution. Some people repopulate their B cells faster than others; one study of multiple sclerosis patients with African ancestry showed earlier reappearance of B cells after treatment, linked to anti-drug antibodies and specific genetic differences.

If you are not on therapy but want a baseline as part of broader immune profiling, retest annually unless something changes (a new diagnosis, persistent infections, a new medication). Compare results within the same lab whenever possible to minimize platform-related noise.

When Results Can Be Misleading

• Recent anti-CD20 infusion: a count near zero shortly after rituximab, ocrelizumab, ofatumumab, ublituximab, or obinutuzumab is expected, not a sign of immune failure. Depletion happens within 1 to 2 weeks of the first dose and lasts for many months.
• Lymphodepleting chemotherapy: regimens given before CAR-T cell therapy intentionally clear lymphocytes including CD20+ B cells, producing very low counts unrelated to your underlying immune health.
• Flow cytometry platform differences: the same blood sample run on different instruments or with different reagent panels can produce different absolute numbers. If you change labs, expect the baseline to shift even if your biology has not changed.
• Active infection or recent vaccination: B cells redistribute between blood and lymphoid tissues during immune activation, which can briefly skew the blood count without reflecting a lasting change.

What to Do With an Unexpected Result

If you are on B-cell-depleting therapy and your CD20+ count is rising earlier than expected, that is information your prescribing physician can use to time your next dose, especially if disease activity is creeping back. If you are not on such therapy and your count is unusually low, consider checking your immunoglobulin levels (IgG, IgA, IgM) to see whether your overall antibody production is intact. If your count is unusually high, especially with abnormal cell populations on the flow cytometry report, that pattern can warrant a hematology consultation to rule out a clonal B-cell process.

This biomarker rarely stands alone. The most useful interpretations come when CD20+ counts are read alongside CD19+ B cells, T-cell subsets (CD3, CD4, CD8), NK cells, and immunoglobulins. Together they give a full picture of which arm of your immune system is working and which is not.